Datum Källa Rubrik Typ Alternativ
2023-06-02 Genovis Genovis AB: Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets Pressreleaser Ladda ner | Visa Stäng
2023-06-02 Genovis Genovis AB: Genovis lanserar unikt IgM-specifikt enzym med breda tillämpningar inom Life Science-marknaden Pressreleaser Ladda ner | Visa Stäng
2023-05-17 Redeye Redeye: Genovis Q1 2023 - Strongest report to date Pressreleaser Ladda ner | Visa Stäng
2023-05-16 Genovis Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-16 Genovis Kommuniké från Årsstämman i Genovis AB (publ) den 16 maj 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-16 Genovis Genovis AB: Interim Report January-March 2023 Rapporter Ladda ner | Visa Stäng
2023-05-16 Genovis Genovis AB: Kvartalsrapport januari-mars 2023 Rapporter Ladda ner | Visa Stäng
2023-05-03 Genovis Genovis AB: Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China Pressreleaser Ladda ner | Visa Stäng
2023-05-03 Genovis Genovis AB: Genovis och ArcticZymes Technologies ingår samarbetsavtal för att accelerera tillväxt på den kinesiska marknaden Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Genovis Genovis AB: Genovis acquires IP Rights to novel enzymes for applications within genomics Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Genovis Genovis AB: Genovis förvärvar patenträttigheter till nytt enzym inom genomics Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Genovis Genovis AB: Genovis årsredovisning 2022 publicerad Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Genovis Genovis AB: Genovis Annual Report 2022 published Pressreleaser Ladda ner | Visa Stäng
2023-04-11 Genovis Genovis AB: NOTICE CONVENING THE 2023 ANNUAL GENERAL MEETING Pressreleaser Ladda ner | Visa Stäng
2023-04-11 Genovis Genovis AB: KALLELSE TILL ÅRSSTÄMMA 2023 Pressreleaser Ladda ner | Visa Stäng
2023-02-16 Redeye Redeye: Genovis Q4 2022 - A First Sublicensing of Xork Pressreleaser Ladda ner | Visa Stäng
2023-02-15 Genovis Genovis AB: Year-end Report January-December 2022 Rapporter Ladda ner | Visa Stäng
2023-02-15 Genovis Genovis AB: Bokslutskommuniké januari-december 2022 Rapporter Ladda ner | Visa Stäng
2023-01-09 Genovis Genovis AB: Genovis erhåller direkt 4 MUSD efter att Selecta Biosciences sub-licensierat Xork™-enzymet till Astellas Pharma Pressreleaser Ladda ner | Visa Stäng
2023-01-09 Genovis Genovis AB: Genovis to receive 4 MUSD upfront after Selecta Biosciences sublicensed Xork™ enzyme to Astellas Pharma Pressreleaser Ladda ner | Visa Stäng
2022-12-12 Redeye Redeye: Genovis - Bull Story, Fair Price Analyser Ladda ner | Visa Stäng
2022-11-15 Genovis Genovis AB: Interim Report January-September 2022 Rapporter Ladda ner | Visa Stäng
Rapporter | 15 Nov 2022 | Genovis

Genovis AB: Interim Report January-September 2022

Comments from Fredrik Olsson, Chief Executive Officer

Sales increased by about 46% in the third quarter, 26% adjusted for currency effects, and we achieved an operating profit of approximately SEK 5 million. 

We note that the influence of the coronavirus pandemic is gradually easing, which has had a positive impact on our customers’ activity. They are returning to a greater extent to the laboratories and projects that are less focused on vaccines and Covid-19-related drug projects.

Sales of enzymes increased by about 44% and we saw growth in all geographic markets, with Asia and North America making the strongest contributions during the quarter. Revenue from gene therapy and bioprocess is expected to contribute to volatility in individual quarters in the short term and in third quarter bioprocess contributed with SEK 1.5 million. The antibody business also saw a strong performance during the quarter, with growth of about 60%. The recently launched service business for antibody analysis have been initiated and first orders have been delivered in the quarter. Overall, our sales performed well and the expansion of our commercial organization, combined with a broader product offering, is reflected in increased customer interaction and new customers.

Our total cost base has increased compared with the corresponding period last year. The increase in the cost of raw materials is largely associated with price increases that have been further accelerated by currency effects, since many of the raw materials are directly linked to other currencies. We have periodically experienced certain supply chain challenges and we are actively working with our suppliers to secure access to raw materials. Personnel costs have increased as a result of the strategic growth initiatives in our commercial organization and associated currency effects.

At the end of the second quarter we launched two new products, GlySERIAS and OmniGLYZOR. Both products have been well received, but GlySERIAS has initially generated tangible commitment among our customers. GlySERIAS mainly focuses on new formats of biopharmaceuticals, outside traditional antibodies, and the customer response has exceeded expectations.

In September, we carried out additional key hires to our commercial organization, in line with the planned strategies for the year. The new members of the commercial organization have been well integrated into our team during the year, thanks to excellent help and support from other parts of the organization, which contributed strongly to the successful initiative.

As yet, we have not experienced any clear impact among our customers due to the geopolitical and macroeconomic situation and the beginning of the fourth quarter has shown continued good customer activity in our various markets.

I would like to conclude by extending a warm thank you to my colleagues at Genovis who do amazing work for our customers every day in their quest to develop new and better treatments for patients around the world.

This disclosure contains information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-11-2022 08:00 CET.

2022-11-15 Genovis Genovis AB: Delårsrapport januari-september 2022 Rapporter Ladda ner | Visa Stäng

Kommande händelser

15 May 2024 | Kvartalsrapport 2024-Q1
15 May 2024 | Årsstämma 2024
16 May 2024 | Årligutdelning
20 Aug 2024 | Kvartalsrapport 2024-Q2
8 Nov 2024 | Kvartalsrapport 2024-Q3
14 Feb 2025 | Bokslutskommuniké 2024